Helus Reports Positive Phase 3 Results For HLP003 In Major Depressive Disorder; Stock Up

Helus Pharma (HELP) reported positive Phase 3 results for HLP003, an adjunctive treatment for major depressive disorder. The trial met its primary endpoint, with a 7.6-point placebo-adjusted benefit on the MADRAS scale. The treatment showed rapid onset and was well-tolerated. The stock rose 22.10% in pre-market trading.

Original reporting
Published Nov 16, 2026, 1:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 1:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$HELP
Bullish
high confidence
Mentioned
$HELP
Relevance
9/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$HELPBullishHigh
01

Why it matters

The Phase 3 data provides a clear catalyst, likely prompting short covering and new buying, especially given the pre‑market price jump.

02

Market read

First‑time disclosure of pivotal trial success, creating immediate trading opportunity.

03

What to watch

Long‑term commercialization risk, pricing pressure, and competition from other novel antidepressants.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Helus Pharma (HELP) is a clinical‑stage biotech focused on serotonergic therapies for mental health disorders.

Company-level read

Ticker impact

$HELPBullishHigh confidence
Context

Helus Pharma reported positive Phase 3 APPROACH trial results for HLP003 in major depressive disorder, driving a pre‑market price rise.

Expected impact

upward pressure as the market absorbs the statistically significant efficacy and safety data.

Evidence & confidence

Phase 3 success is a material catalyst for a biotech; the stock already jumped 22% pre‑market, indicating strong buying interest.

Market effects

Positive MDD trial data may lift sentiment across the psychiatric‑drug biotech sector.

Boosts US biotech market activity and could attract regional investors.

Potential worldwide interest in a new antidepressant therapy.

Counterpoint

Some analysts may caution that safety signals or regulatory hurdles could temper upside.

Key entities

  • Helus Pharma

    Biotech developer of HLP003 for major depressive disorder.

Related articles

$HELPMed

HELP Stock Slides As Suicide Attempt Overshadows Strong Late-stage Depression Trial Data

HELP stock declined despite positive late-stage trial data for its depression drug, HLP003. The drug showed significant improvements in patients, with 56% seeing at least a 50% improvement at six weeks. Analysts like Lucid Capital raised their price target to $79, citing strong results, while Jefferies and Barclays maintained 'Buy' and 'Overweight' ratings, respectively. Retail sentiment on Stocktwits turned 'extremely bullish'.

$HELPMedAI 8/10

Helus Pharma falls 10.5% despite positive HLP003 trial

Helus Pharma (HELP) reported positive results for its experimental drug HLP003, meeting the primary endpoint in a late-stage depression trial. Despite this, shares fell 10.5% to $7.94, with three serious adverse events disclosed. Analysts noted strong efficacy and no fundamental reason for the decline. The company is also developing HLP004 for anxiety and expects to identify an HLP005 candidate in late 2027.

MedAI 8/10

Serious adverse events mar robust efficacy data for Helus’ psychedelic in major depression

Helus Pharma reported that its deuterated psilocin therapy, HLP003, significantly reduced major depressive disorder symptoms in a late-stage trial, but its stock fell due to three undisclosed serious adverse events. The trial met primary and secondary endpoints, with a 19.5-point reduction in symptoms versus 11.9 for placebo. Analysts noted the efficacy but emphasized the need for safety clarification. The company expects further trial results in 2027.

HighAI 8/10

Helus Pharma's psychedelic depression drug succeeds in late-stage study, shares jump

Helus Pharma reported that its psychedelic drug, HLP003, showed significant improvement in depression symptoms in a late-stage trial. The drug, a modified version of psilocin, is designed to be used with standard antidepressants. The company's shares rose over 20% in premarket trading. According to Helus, 56.3% of patients treated with HLP003 saw their symptoms cut by at least half, compared with 28.2% on placebo.